Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme
Top Cited Papers
- 20 December 2005
- journal article
- neurooncology
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (36) , 9359-9368
- https://doi.org/10.1200/jco.2005.03.2185
Abstract
Purpose We performed a phase II study to evaluate the combination of imatinib mesylate, an adenosine triphosphate mimetic, tyrosine kinase inhibitor, plus hydroxyurea, a ribonucleotide reductase in...Keywords
This publication has 54 references indexed in Scilit:
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Distribution of STI-571 to the Brain Is Limited by P-Glycoprotein-Mediated EffluxThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseBritish Journal of Cancer, 2000
- Pharmacokinetics and Pharmacodynamics of HydroxyureaClinical Pharmacokinetics, 1998
- Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loopInternational Journal of Cancer, 1995
- Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studiesEuropean Journal of Drug Metabolism and Pharmacokinetics, 1991